% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • Isaac_dj Isaac_dj Dec 30, 2003 5:39 PM Flag

    CEO OWNS 1.08 Million Shrs as in 2002 !

    According to NASDAQ, Josh Boger, the CEO of VRTX, owns 1.08 million shares of VRTX -- exactly the number of shares he owned in Aug, 2002.

    In fact, he owns more VRTX shares than Morgan Stanley, the 11th largest institutional owner in VRTX.


    Few CEOs of biotech companies have such a large investment in their stocks. CLEARLY, Josh Boger has more at risk here than most VRTX-owning institutions (except for the top 10).


    In other words, there is clearly no chance that he will decline a good offer.

    Think about it. But DON'T BE FOOLED by disinformation posted on this board (particularly by shorts and bashers whose intentions are clear).

    Good Luck to ALL!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Shhhh...don't wake him up. Let him keep on dreaming. He's got himself convinced, and now he's trying to convince others. I hope SPG is reading this board.

    • VRTX will be acquired in 2004 and SOONER than later.

      I am betting that SGP will beat Roche to this punch.

      Actually, SGP has no choice in this case if it wants to regain its dominance in the HCV market.

      And certainly, if SGP decides to wait till after the results of the PIVOTAL TRIAL of Merimepodib, not only will it have to pay a MUCH HIGHER PRICE but it also takes the risk that another company will make a move for VRTX. For these reasons, SGP will be FORCED TO ACT QUICKLY in this case.

      Any way one analyzes the VRTX situation, the fact that Merimepodib achieved a virologic response in 86% of HCV patients who were NON-RESPONSIVE TO IFN + Ribavirin therapy, makes VRTX extremely attractive to companies with a large market share in the HCV market (e.g., SGP, Roche, etc.). For the company that acquires VRTX will clearly gain a tremendous advantage over its competition in this $2.5 billion market. Also, the high efficacy of Merimepodib (in combination with PEG-IFN and Ribavirin) will certainly increase, by at least 50%, the number of patients taking a full-duration treatment of PEG-IFN and Ribavirin.

      Keep in mind the 24-week results of Merimepodib were achieved in patients who ALL had HCV genotype 1 -- the most difficult to achieve a virologic response in and the most common genotype in the US.

      Think about it. But DON'T BE FOOLED by disinformation posted on this board.

      For more analysis of SGP's likely move, see:

      Good Luck to ALL!

      • 1 Reply to isaac_dji
      • <<VRTX will be acquired in 2004 and SOONER than later>>

        I believe you or somewone else also said in a previous posts that there will be a friendly takeover.

        I will not count on a friendly takeover. Any body who has watched Boger's actions since he was at Merck and knows why he left and has watched him mange VRTX knows that he has a very BIG ego--one of the reasons he blew millions of our shareholder dollars on Aurora and other stupid companies as well as getting into big unneeded lease agreements that we lost I believe $50+ mil on. This big ego would not allow him to sell the company since he won't be the number one in the company any more. Regardless of how much they offer for VRTX I do not believe he will sell.

        Now as far as an unfriendly takeover is concerned, he has made sure there is a big poison pill in place. The question is, is there a big pharma willing to get involved in fighting the poison pill in courts. I do not have the answer to that!

    • 1.08 million shares @ $30+ is why it is real easy to sell. YES "SGP" WILL OWN VRTX JANUARY
      2004. "COUNT ON IT". I AGREE 100%

97.09+0.71(+0.74%)Aug 26 4:00 PMEDT